Impact of posttranslational modifications in pancreatic carcinogenesis and treatments
- PMID: 34342796
- DOI: 10.1007/s10555-021-09980-4
Impact of posttranslational modifications in pancreatic carcinogenesis and treatments
Abstract
Pancreatic cancer (PC) is a highly aggressive cancer, with a 9% 5-year survival rate and a high risk of recurrence. In part, this is because PC is composed of heterogeneous subgroups with different biological and functional characteristics and personalized anticancer treatments are required. Posttranslational modifications (PTMs) play an important role in modifying protein functions/roles and are required for the maintenance of cell viability and biological processes; thus, their dysregulation can lead to disease. Different types of PTMs increase the functional diversity of the proteome, which subsequently influences most aspects of normal cell biology or pathogenesis. This review primarily focuses on ubiquitination, SUMOylation, and NEDDylation, as well as the current understanding of their roles and molecular mechanisms in pancreatic carcinogenesis. Additionally, we briefly summarize studies and clinical trials on PC treatments to advance our knowledge of drugs available to target the ubiquitination, SUMOylation, and NEDDylation PTM types. Further investigation of PTMs could be a critical field of study in relation to PC, as they have been implicated in the initiation and progression of many other types of cancer.
Keywords: NEDDylation; Pancreatic carcinogenesis; Posttranslational modification; SUMOylation; Treatments; Ubiquitination.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer.Int J Mol Sci. 2022 Mar 23;23(7):3480. doi: 10.3390/ijms23073480. Int J Mol Sci. 2022. PMID: 35408841 Free PMC article. Review.
-
Modifications in the cellular proteome and their clinical application.Medicina (B Aires). 2019;79(Spec 6/1):570-575. Medicina (B Aires). 2019. PMID: 31864228 Review. English.
-
Crosstalk between Ubiquitination and Other Post-translational Protein Modifications in Plant Immunity.Plant Commun. 2020 Mar 25;1(4):100041. doi: 10.1016/j.xplc.2020.100041. eCollection 2020 Jul 13. Plant Commun. 2020. PMID: 33367245 Free PMC article. Review.
-
The involvement of post-translational modifications in cardiovascular pathologies: Focus on SUMOylation, neddylation, succinylation, and prenylation.J Mol Cell Cardiol. 2020 Jan;138:49-58. doi: 10.1016/j.yjmcc.2019.11.146. Epub 2019 Nov 18. J Mol Cell Cardiol. 2020. PMID: 31751566 Review.
-
The Role of SUMOylation and Ubiquitination in Brain Ischaemia: Critical Concepts and Clinical Implications.Curr Issues Mol Biol. 2020;35:127-144. doi: 10.21775/cimb.035.127. Epub 2019 Aug 18. Curr Issues Mol Biol. 2020. PMID: 31422937 Review.
Cited by
-
USPs in Pancreatic Ductal Adenocarcinoma: A Comprehensive Bioinformatic Analysis of Expression, Prognostic Significance, and Immune Infiltration.Biomed Res Int. 2022 Dec 20;2022:6109052. doi: 10.1155/2022/6109052. eCollection 2022. Biomed Res Int. 2022. PMID: 36582601 Free PMC article.
-
Dysregulation of SIRT3 SUMOylation Confers AML Chemoresistance via Controlling HES1-Dependent Fatty Acid Oxidation.Int J Mol Sci. 2022 Jul 27;23(15):8282. doi: 10.3390/ijms23158282. Int J Mol Sci. 2022. PMID: 35955415 Free PMC article.
-
Posttranslational modifications in pathogenesis of PCOS.Front Endocrinol (Lausanne). 2022 Oct 7;13:1024320. doi: 10.3389/fendo.2022.1024320. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36277727 Free PMC article. Review.
-
Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway.Front Oncol. 2022 Jan 26;12:822039. doi: 10.3389/fonc.2022.822039. eCollection 2022. Front Oncol. 2022. PMID: 35155257 Free PMC article.
-
Modification of lysine-260 2-hydroxyisobutyrylation destabilizes ALDH1A1 expression to regulate bladder cancer progression.iScience. 2023 Oct 5;26(11):108142. doi: 10.1016/j.isci.2023.108142. eCollection 2023 Nov 17. iScience. 2023. PMID: 37867947 Free PMC article.
References
-
- Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA A Cancer Journal for Clinicians, 69(1), 7–34. https://doi.org/10.3322/caac.21551 - DOI - PubMed
-
- Real, F. X. (2003). A “catastrophic hypothesis” for pancreas cancer progression. Gastroenterology, 124(7), 1958–1964. https://doi.org/10.1016/s0016-5085(03)00389-5 - DOI - PubMed
-
- Srivastava, S., Koay, E. J., Borowsky, A. D., De Marzo, A. M., Ghosh, S., Wagner, P. D., et al. (2019). Cancer overdiagnosis: A biological challenge and clinical dilemma. Nature Reviews Cancer, 19(6), 349–358. https://doi.org/10.1038/s41568-019-0142-8 - DOI - PubMed
-
- Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., et al. (2019). Cancer treatment and survivorship statistics, 2019. CA A Cancer Journal for Clinicians, 69(5), 363–385. https://doi.org/10.3322/caac.21565 - DOI - PubMed
-
- van Huijgevoort, N. C. M., Del Chiaro, M., Wolfgang, C. L., van Hooft, J. E., & Besselink, M. G. (2019). Diagnosis and management of pancreatic cystic neoplasms: Current evidence and guidelines. Nature Reviews. Gastroenterology & Hepatology, 16(11), 676–689. https://doi.org/10.1038/s41575-019-0195-x - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous